Clinical Trials

Glycotex is developing a novel class of drugs intended to accelerate human wound healing and tissue repair in acute and chronic wounds. Its lead product candidate, GLYC-101, is initially being developed for burn wounds, traumatic and surgical wounds, diabetic ulcers and venous ulcers.

GLYC-101 for Burn Wounds
GLYC-101 is currently in a double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the effect of GLYC-101 on wound closure and other clinical endpoints for the treatment of clinically induced burn wounds [see press release]. In a pre-clinical mini-porcine model, there was a complete restitution of physiologic skin histology after 5 days of treatment.

GLYC-101 for Chronic Venous Ulcers
A Phase II clinical trial of GLYC-101 for the treatment of venous ulcers, conducted in Australia, was completed in May, 2006. In this trial, GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard treatment in patients with chronic venous ulcers. The results of this trial provided proof-of concept and dose-ranging information for GLYC-101.

Clinical Pipeline
In 2009, Glycotex expects to initiate in the U.S. a series of Phase II clinical trials evaluating GLYC-101 in several indications. We expect these trials to generate important clinical data that will determine which indications to advance into registration trials leading to product approval.